Related Experiment Video
Updated: Feb 22, 2026
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
Fibro-Mark: a panel of laboratory parameters for predicting significant fibrosis in chronic hepatitis C patients
A M Attallah1, D Omran2, M M Omran3
1a Research & Development Dept. , Biotechnology Research Center , New Damietta , Egypt.
Insights
A new Fibro-Mark score, incorporating novel biomarkers, shows superior accuracy in identifying liver fibrosis in chronic hepatitis C patients compared to existing clinical scores.
Area of Science:
- Hepatology
- Biomarker Discovery
- Diagnostic Accuracy
Background:
- Existing clinical scores for liver fibrosis, such as APRI and King's score, have limited accuracy in diagnosing significant fibrosis.
- New markers reflecting fibrogenesis and fibrolysis are needed to improve fibrosis assessment.
- Hepatic fibrosis is a critical predictor of cirrhosis and its complications.
Purpose of the Study:
- To develop and validate a novel, more sensitive, and specific score for identifying significant liver fibrosis.
- To evaluate the diagnostic performance of the new score against established fibrosis assessment tools.
Main Methods:
- Measured novel markers (Collagen IV, hyaluronic acid, PDGF, TIMP-1) and routine clinical data in 148 hepatitis C patients.
- Utilized stepwise linear discriminant analysis and ROC curve analysis to develop and compare predictive scores.
- Assessed fibrosis staging using standard pathological criteria.
Main Results:
- Significant fibrosis (F2-F4) was associated with increased levels of Collagen IV, hyaluronic acid, PDGF, and TIMP-1.
- A five-marker score, Fibro-Mark (including AFP, age, PDGF, Collagen IV, TIMP-1), demonstrated high predictive accuracy (AUC 0.89).
- Fibro-Mark outperformed existing scores like BRC, FRT, King's score, APRI, Fibro-α, and FibroQ in discriminating significant fibrosis.
Conclusions:
- The Fibro-Mark score offers improved diagnostic discrimination for hepatic fibrosis staging in chronic hepatitis C.
- This novel score has the potential to enhance clinical decision-making in managing liver disease.
- Further validation in diverse patient populations is warranted.
Background:
Fibrosis markers are useful for the prediction of cirrhosis but clinical scores such as King's score, AST-Platelet ratio index (APRI), Biotechnology research center (BRC), Fibrosis routine test (FRT), Fibro-α score and Fibro-quotient (FibroQ) have limited accuracy for diagnosing significant fibrosis. We hypothesised that new markers (reflecting the balance between hepatic fibrogenesis and fibrolysis) together with other indirect fibrosis markers would together construct a more sensitive and specific score capable of identifying fibrosis than existing scores.
Methods:
Collagen IV, hyaluronic acid, platelet-derived growth factor (PDGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured by ELISA, and AST, ALT, platelet count, albumin, total bilirubin, INR and AFP by routine methods in 148 patients with hepatitis C induced liver disease. Stepwise linear discriminant analysis and area under receiver-operating characteristic curves (AUCs) were used to create a predictive score and compare it to others.
Results:
Patients with significant fibrosis (n = 100, F2-F4) showed 2.08, 2.14, 1.80 and 1.90-fold increase in collagen IV, hyaluronic acid, PDGF and TIMP-1, respectively, over patients with no or mild fibrosis (n = 48, F0/F1)(all p < 0.01). Significant independent predictors of F2-F4 were AFP (AUC 0.79), age (0.76), PDGF (0.74), collagen IV (0.78) and TIMP (0.75), which together formed a five-marker score 'Fibro-Mark' for predicting F2-F4. In comparison with other scores, AUC for Fibro-Mark was 0.89, BRC was 0.83, followed by FRT and King's score (both 0.82), APRI (0.80), Fibro-α (0.70) and finally Fibro Q (0.63).
Conclusions:
The Fibro-Mark score provides better discrimination in hepatic-fibrosis staging in chronic hepatitis C patients than existing scores.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
06:26Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow